Global Oral Cancer Diagnosis Market
Description
MARKET SCOPE:
The global Oral Cancer Diagnosis market is projected to grow significantly, registering a CAGR of 7.9% during the forecast period (2024 – 2032).
Oral cancer diagnosis involves identifying and confirming the presence of cancerous conditions within the oral cavity, encompassing areas such as the lips, tongue, cheeks, gums, and the roof and floor of the mouth. This process employs various methods and techniques to detect abnormal cell growth or tumors, enabling early intervention and appropriate treatment. Timely diagnosis is critical for enhancing the likelihood of successful treatment and minimizing the impact of oral cancer on an individual's health. Early detection is vital for effective treatment. Factors contributing to the risk of oral cancer include tobacco use, excessive alcohol consumption, human papillomavirus (HPV) infection, sun exposure (for lip cancer), and a family history of oral cancer. Regular dental check-ups, self-examinations, and awareness of potential symptoms can play a crucial role in early diagnosis, leading to improved outcomes for individuals at risk of oral cancer.
MARKET OVERVIEW:
Driver: Increasing prevalence of cancer worldwide is driving the market growth.
In recent years, the significance of oral cancer diagnostics has been on the rise due to the increasing incidence of oral cancer cases. According to a 2017 report from the National Institutes of Health (NIH), an estimated 370,309 individuals were affected by pharynx cancer and oral cavity cancer. Additionally, there was an annual increase of around 3% in newly reported cases of pharynx and oral cancer. The continuous growth in the prevalence of oral cancer has driven advancements in technology to enhance facilities and diagnostic tools, influencing the expansion of the market. Furthermore, major drivers of the market include the rising consumption of tobacco, alcohol, and cancers induced by the human papillomavirus (HPV).
Opportunities: Government Initiatives and improvement in the testing methods are expected to pave the way for market growth in the upcoming years.
Several companies are focusing on enhancing testing methods and equipment used during routine tests for individuals affected by cancer. They are working on the development of equipment known as Oral Cancer Rapid Testing Kit (OCRTK). This equipment has the capability to detect oral cancer in a shorter time frame and in an efficient manner. Technological advancements and the innovation of new and convenient products are expected to drive the global oral cancer market. The necessary components for these advancements include RNA, lipids, exosomes, and DNA. The emergence of new technologies that enhance immunity has increased opportunities for the development of oral cancer tests.
COVID IMPACT:
The onset of the COVID-19 pandemic has significantly influenced the oral cancer diagnostics market, causing notable disruptions, particularly in healthcare facilities, especially in underdeveloped countries in Africa and other developing regions. The entire cancer diagnosis sector, encompassing routine tests, screenings, patient follow-ups, and related activities, has experienced adverse effects. The disruptions induced by COVID-19 have heightened health risks for individuals diagnosed with cancer, leading to challenges such as delays in diagnosis, initiation of treatment, and the ongoing healthcare management for oral cancer patients. These disruptions have underscored the importance of addressing broader healthcare infrastructure issues and adapting strategies to ensure the continuity of essential diagnostic and treatment services during global health crises.
SEGMENTATION ANALYSIS:
The Oral squamous cell carcinoma segment is anticipated to grow significantly during the forecast period.
Oral squamous cell carcinoma (OSCC) stands as the most prominent segment, given its elevated prevalence among individuals worldwide. This type of carcinoma is found in the squamous cells that line the oral cavity. OSCC is closely linked to tobacco use, alcohol consumption, and HPV infection. Moreover, the increasing focus on research and innovation in OSCC, resulting in a range of treatment options including surgery, radiation therapy, chemotherapy, and targeted therapy, is contributing to market growth. Additionally, the growing awareness of risk factors and the intensified efforts for early detection and screening programs are further amplifying market growth.
The Hospitals and Clinic segment is anticipated to grow significantly during the forecast period.
The hospitals segment has obtained the leading share in the market, with this dominance attributed to the growing number of patients seeking medical care in hospitals. Additionally, the increasing prevalence of in-house diagnostic procedures conducted within hospital settings and a heightened awareness of the importance of early diagnosis contribute to the significant growth and prominence of the hospitals segment in the market.
REGIONAL ANALYSIS:
The North American region is set to witness significant growth during the forecast period.
The North and South America region is projected to be the dominant force in the oral cancer diagnostics market throughout the forecast period. This can be attributed to the presence of numerous key market players, a rising number of oral cancer cases, well-established and advanced technologies, as well as supportive government policies in developed countries such as Canada and the U.S. North America holds the largest market share, attributed to its advanced healthcare infrastructure and the presence of leading pharmaceutical and biotechnology companies actively involved in cancer research. The market is further propelled by the increasing prevalence of oral cancer linked to lifestyle factors such as tobacco and alcohol use. Moreover, the robust emphasis on cancer research aimed at developing novel treatment modalities, including targeted therapies and immunotherapies, serves as a key driver for market growth. Additionally, well-established healthcare policies and reimbursement frameworks that facilitate access to cancer treatment contribute significantly to the overall market expansion.
COMPETITIVE ANALYSIS
The global Oral Cancer Diagnosis market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.
GE Healthcare
Roche Diagnostics
Becton, Dickinson and Company
Bristol Myers Squibb
Merck & Co. Inc
Siemens Healthineers
Hitachi Ltd
Vigilant Biosciences, Inc.
SCOPE OF THE REPORT
By Indication
It provides a technological development map over time to understand the industry’s growth rate and indicates how the Oral Cancer Diagnosis market is evolving.
The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which Oral Cancer Diagnosis submarket will be the main driver of the overall market from 2024 to 2032.
It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.
It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032.
The global Oral Cancer Diagnosis market is projected to grow significantly, registering a CAGR of 7.9% during the forecast period (2024 – 2032).
Oral cancer diagnosis involves identifying and confirming the presence of cancerous conditions within the oral cavity, encompassing areas such as the lips, tongue, cheeks, gums, and the roof and floor of the mouth. This process employs various methods and techniques to detect abnormal cell growth or tumors, enabling early intervention and appropriate treatment. Timely diagnosis is critical for enhancing the likelihood of successful treatment and minimizing the impact of oral cancer on an individual's health. Early detection is vital for effective treatment. Factors contributing to the risk of oral cancer include tobacco use, excessive alcohol consumption, human papillomavirus (HPV) infection, sun exposure (for lip cancer), and a family history of oral cancer. Regular dental check-ups, self-examinations, and awareness of potential symptoms can play a crucial role in early diagnosis, leading to improved outcomes for individuals at risk of oral cancer.
MARKET OVERVIEW:
Driver: Increasing prevalence of cancer worldwide is driving the market growth.
In recent years, the significance of oral cancer diagnostics has been on the rise due to the increasing incidence of oral cancer cases. According to a 2017 report from the National Institutes of Health (NIH), an estimated 370,309 individuals were affected by pharynx cancer and oral cavity cancer. Additionally, there was an annual increase of around 3% in newly reported cases of pharynx and oral cancer. The continuous growth in the prevalence of oral cancer has driven advancements in technology to enhance facilities and diagnostic tools, influencing the expansion of the market. Furthermore, major drivers of the market include the rising consumption of tobacco, alcohol, and cancers induced by the human papillomavirus (HPV).
Opportunities: Government Initiatives and improvement in the testing methods are expected to pave the way for market growth in the upcoming years.
Several companies are focusing on enhancing testing methods and equipment used during routine tests for individuals affected by cancer. They are working on the development of equipment known as Oral Cancer Rapid Testing Kit (OCRTK). This equipment has the capability to detect oral cancer in a shorter time frame and in an efficient manner. Technological advancements and the innovation of new and convenient products are expected to drive the global oral cancer market. The necessary components for these advancements include RNA, lipids, exosomes, and DNA. The emergence of new technologies that enhance immunity has increased opportunities for the development of oral cancer tests.
COVID IMPACT:
The onset of the COVID-19 pandemic has significantly influenced the oral cancer diagnostics market, causing notable disruptions, particularly in healthcare facilities, especially in underdeveloped countries in Africa and other developing regions. The entire cancer diagnosis sector, encompassing routine tests, screenings, patient follow-ups, and related activities, has experienced adverse effects. The disruptions induced by COVID-19 have heightened health risks for individuals diagnosed with cancer, leading to challenges such as delays in diagnosis, initiation of treatment, and the ongoing healthcare management for oral cancer patients. These disruptions have underscored the importance of addressing broader healthcare infrastructure issues and adapting strategies to ensure the continuity of essential diagnostic and treatment services during global health crises.
SEGMENTATION ANALYSIS:
The Oral squamous cell carcinoma segment is anticipated to grow significantly during the forecast period.
Oral squamous cell carcinoma (OSCC) stands as the most prominent segment, given its elevated prevalence among individuals worldwide. This type of carcinoma is found in the squamous cells that line the oral cavity. OSCC is closely linked to tobacco use, alcohol consumption, and HPV infection. Moreover, the increasing focus on research and innovation in OSCC, resulting in a range of treatment options including surgery, radiation therapy, chemotherapy, and targeted therapy, is contributing to market growth. Additionally, the growing awareness of risk factors and the intensified efforts for early detection and screening programs are further amplifying market growth.
The Hospitals and Clinic segment is anticipated to grow significantly during the forecast period.
The hospitals segment has obtained the leading share in the market, with this dominance attributed to the growing number of patients seeking medical care in hospitals. Additionally, the increasing prevalence of in-house diagnostic procedures conducted within hospital settings and a heightened awareness of the importance of early diagnosis contribute to the significant growth and prominence of the hospitals segment in the market.
REGIONAL ANALYSIS:
The North American region is set to witness significant growth during the forecast period.
The North and South America region is projected to be the dominant force in the oral cancer diagnostics market throughout the forecast period. This can be attributed to the presence of numerous key market players, a rising number of oral cancer cases, well-established and advanced technologies, as well as supportive government policies in developed countries such as Canada and the U.S. North America holds the largest market share, attributed to its advanced healthcare infrastructure and the presence of leading pharmaceutical and biotechnology companies actively involved in cancer research. The market is further propelled by the increasing prevalence of oral cancer linked to lifestyle factors such as tobacco and alcohol use. Moreover, the robust emphasis on cancer research aimed at developing novel treatment modalities, including targeted therapies and immunotherapies, serves as a key driver for market growth. Additionally, well-established healthcare policies and reimbursement frameworks that facilitate access to cancer treatment contribute significantly to the overall market expansion.
COMPETITIVE ANALYSIS
The global Oral Cancer Diagnosis market is reasonably competitive with mergers, acquisitions, and product launches. See some of the major key players in the market.
GE Healthcare
- In 2020, GE Healthcare has collaborated with GenesisCare to enhance patient outcomes for two major global health concerns—cancer and heart disease. Under this partnership, GE Healthcare will supply CT, MRI, PET/CT, SPECT, digital mammography, and ultrasound equipment to GenesisCare's network of over 440 treatment centers specializing in cancer and cardiovascular disease treatment across Australia, the United States, the United Kingdom, and Spain.
- In 2020, Roche Diagnostics has established a partnership with Illumina to facilitate widespread access to clinical oncology next-generation sequencing.
Roche Diagnostics
Becton, Dickinson and Company
Bristol Myers Squibb
Merck & Co. Inc
Siemens Healthineers
Hitachi Ltd
Vigilant Biosciences, Inc.
SCOPE OF THE REPORT
By Indication
- Oral Squamous Cell Carcinoma
- Oral Verrucous Carcinoma
- Mucoepidermoid Carcinoma
- Oral Cavity Lymphomas
- Endoscopy
- Biopsy
- X-Ray
- Computed Tomography (CT)
- Positron Emission Tomography (PET)
- Magnetic Resonance Imaging (MRI)
- Ultrasonography
- Fluorescence Imaging
- Hospitals and Clinic
- Research and Academic Institutes
- North America (the United States & Canada)
- Europe (Germany, UK, France, Spain, Italy, and the Rest of Europe)
- Asia Pacific (China, Japan, India, and Rest of Asia Pacific)
- Rest of the World (the Middle East & Africa, and Latin America)
It provides a technological development map over time to understand the industry’s growth rate and indicates how the Oral Cancer Diagnosis market is evolving.
The report offers a dynamic method to various factors that drive or restrain the growth of the market and specifies which Oral Cancer Diagnosis submarket will be the main driver of the overall market from 2024 to 2032.
It renders a definite analysis of changing competitive dynamics and stipulates the leading players and what are their prospects over the forecast period.
It builds a nine-year estimate based on how the market is predicted to grow and shows what will market shares of the global region change by 2032 and which country will lead the market in 2032.
Table of Contents
199 Pages
- 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Regional Analysis
- 1.3. Segment Analysis
- 2. Overview And Scope
- 2.1. Market Vision
- 2.1.1. Market Definition
- 2.2. Market Segmentation
- 3. Global Oral Cancer Diagnosis Market Overview By Region: 2019 Vs 2023 Vs 2032
- 3.1. Global Oral Cancer Diagnosis Market Size By Regions (2019-2023) (Usd Million)
- 3.1.1. North America Oral Cancer Diagnosis Market Size By Country (2019-2023) (Usd Million)
- 3.1.2. Europe Oral Cancer Diagnosis Market Size By Country (2019-2023) (Usd Million)
- 3.1.3. Asia Pacific America Oral Cancer Diagnosis Market Size By Country (2019-2023) (Usd Million)
- 3.1.4. Rest Of The World Oral Cancer Diagnosis Market Size By Country (2019-2023) (Usd Million)
- 3.2. Global Oral Cancer Diagnosis Market Size By Regions (2024-2032) (Usd Million)
- 3.2.1. North America Oral Cancer Diagnosis Market Size By Country (2024-2032) (Usd Million)
- 3.2.2. Europe Oral Cancer Diagnosis Market Size By Country (2024-2032) (Usd Million)
- 3.2.3. Asia Pacific Oral Cancer Diagnosis Market Size By Country (2024-2032) (Usd Million)
- 3.2.4. Rest Of The World Oral Cancer Diagnosis Market Size By Country (2024-2032) (Usd Million)
- 4. Global Oral Cancer Diagnosis Market Dynamics
- 4.1. Market Overview
- 4.1.1. Market Drivers
- 4.1.2. Market Restraints/ Challenges Analysis
- 4.1.3. Market Opportunities
- 4.2. Pestle Analysis
- 4.3. Porter’s Five Forces Model
- 4.3.1. Bargaining Power Of Suppliers
- 4.3.2. Bargaining Power Of Buyers
- 4.3.3. The Threat Of New Entrants
- 4.3.4. Threat Of Substitutes
- 4.3.5. Intensity Of Rivalry
- 4.4. Value Chain Analysis/Supply Chain Analysis
- 4.5. Covid-19 Impact Analysis On Global Oral Cancer Diagnosis Market
- ** In – Depth Qualitative Analysis Will Be Provided In The Final Report Subject To Market
- 5. Global Oral Cancer Diagnosis Market, By Indication
- 5.1. Overview
- 5.2. Global Oral Cancer Diagnosis Market Size By Indication
- 5.3. Key Findings For Oral Cancer Diagnosis Market - By Indication
- 5.3.1. Oral Squamous Cell Carcinoma
- 5.3.2. Oral Verrucous Carcinoma
- 5.3.3. Mucoepidermoid Carcinoma
- 5.3.4. Oral Cavity Lymphomas
- 6. Global Oral Cancer Diagnosis Market, By Diagnosis Type
- 6.1. Overview
- 6.2. Key Findings For Oral Cancer Diagnosis Market - By Diagnosis Type
- 6.2.1. Endoscopy
- 6.2.2. Biopsy
- 6.2.3. X-ray
- 6.2.4. Computed Tomography (Ct)
- 6.2.5. Positron Emission Tomography (Pet)
- 6.2.6. Magnetic Resonance Imaging (Mri)
- 6.2.7. Ultrasonography
- 6.2.8. Fluorescence Imaging
- 7. Global Oral Cancer Diagnosis Market, By End User
- 7.1. Overview
- 7.2. Key Findings For Oral Cancer Diagnosis Market - By End User
- 7.2.1. Hospitals And Clinic
- 7.2.2. Research And Academic Institutes
- 8. Global Oral Cancer Diagnosis Market, By Region
- 8.1. Overview
- 8.2. Key Findings For Oral Cancer Diagnosis Market- By Region
- 8.3. Global Oral Cancer Diagnosis Market, By Indication
- 8.4. Global Oral Cancer Diagnosis Market, By Diagnosis Type
- 8.5. Global Oral Cancer Diagnosis Market, By End User
- 9. Global Oral Cancer Diagnosis Market- North America
- 9.1. Overview
- 9.2. North America Oral Cancer Diagnosis Market Size (2019 - 2032) (Usd Million)
- 9.3. North America Oral Cancer Diagnosis Market, By Indication
- 9.4. North America Oral Cancer Diagnosis Market, By Diagnosis Type
- 9.5. North America Oral Cancer Diagnosis Market, By End User
- 9.6. North America Oral Cancer Diagnosis Market Size By Countries
- 9.6.1. United States
- 9.6.2. Canada
- 10. Global Oral Cancer Diagnosis Market- Europe
- 10.1. Overview
- 10.2. Europe Oral Cancer Diagnosis Market Size (2019 - 2032) (Usd Million)
- 10.3. Europe Oral Cancer Diagnosis Market, By Indication
- 10.4. Europe Oral Cancer Diagnosis Market, By Diagnosis Type
- 10.5. Europe Oral Cancer Diagnosis Market, By End User
- 10.6. Europe Oral Cancer Diagnosis Market Size By Countries
- 10.6.1. Germany
- 10.6.2. Uk
- 10.6.3. France
- 10.6.4. Spain
- 10.6.5. Italy
- 10.6.6. Rest Of Europe
- 11. Global Oral Cancer Diagnosis Market - Asia Pacific
- 11.1. Overview
- 11.2. Asia Pacific Oral Cancer Diagnosis Market Size (2019 - 2032) (Usd Million)
- 11.3. Asia Pacific Oral Cancer Diagnosis Market, By Indication
- 11.4. Asia Pacific Oral Cancer Diagnosis Market, By Diagnosis Type
- 11.5. Asia Pacific Oral Cancer Diagnosis Market, By End User
- 11.6. Asia Pacific Oral Cancer Diagnosis Market Size By Countries
- 11.6.1. China
- 11.6.2. Japan
- 11.6.3. India
- 11.6.4. Rest Of Asia Pacific
- 12. Global Oral Cancer Diagnosis Market- Rest Of World
- 12.1. Overview
- 12.2. Rest Of World Oral Cancer Diagnosis Market Size (2019 - 2032) (Usd Million)
- 12.3. Rest Of World Oral Cancer Diagnosis Market, By Indication
- 12.4. Rest Of World Oral Cancer Diagnosis Market, By Diagnosis Type
- 12.5. Rest Of World Oral Cancer Diagnosis Market, By End User
- 12.6. Rest Of World Oral Cancer Diagnosis Market Size By Regions
- 12.6.1. Middle East & Africa
- 12.6.2. Latin America
- 13. Global Oral Cancer Diagnosis Market- Competitive Landscape
- 13.1. Key Strategies Adopted By The Leading Players
- 13.2. Recent Developments
- 13.2.1. Investments & Expansions
- 13.2.2. New End-user Launches
- 13.2.3. Mergers & Acquisitions
- 13.2.4. Agreements, Joint Ventures, And Partnerships
- 14. Global Oral Cancer Diagnosis Market- Company Profiles
- 14.1. Ge Healthcare
- 14.1.1. Company Overview
- 14.1.2. Financial Overview
- 14.1.3. Product Offered
- 14.1.4. Key Developments
- 14.2. Roche Diagnostics
- 14.3. Becton, Dickinson And Company
- 14.4. Bristol Myers Squibb
- 14.5. Merck & Co. Inc
- 14.6. Siemens Healthineers
- 14.7. Hitachi Ltd
- 14.8. Vigilant Biosciences, Inc.
- 15. Our Research Methodology
- 15.1. Data Triangulation
- 15.2. Data Sources
- 15.2.1. Secondary Sources
- 15.2.2. Primary Sources
- 15.3. Assumptions/ Limitations For The Study
- 15.4. Research & Forecasting Methodology
- 16. Appendix
- 16.1. Disclaimer
- 16.2. Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
